14684-5 |
Creatinine |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Creatinine [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/24 H |
|
|
|
|
|
|
CHEM |
|
14684-5 |
|
|
|
|
Both |
|
|
|
0 |
Creat 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Chemistry; CR; Crea; Creat; Kidney; Nephrology; QNT; Quan; Quant; Quantitative; Renal; sRate; Substance Rate; UA; UCr; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
14685-2 |
Cobalamins |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L;nmol/L |
|
|
|
|
|
|
CHEM |
|
14685-2 |
|
|
|
|
Both |
|
|
|
0 |
Vit B12 SerPl-sCnc |
|
|
|
Y |
|
C721; Cbl; Chemistry; Cobalamin; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Vit B12; Vitamin B12 |
2.73 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
14686-0 |
Cystine |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Cystine [Presence] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14686-0 |
|
|
|
|
Observation |
|
|
|
0 |
Cystine Stone Ql |
|
|
|
|
|
Calc; Calculi; Chemistry; Cys-Cys; Dicysteine; Gastro; Gastroenterology; GI; Kidney; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; Stn; Stone; Stones |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14687-8 |
Transfusion date |
TmStp |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Transfusion date |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14687-8 |
|
|
|
|
Observation |
|
|
|
0 |
Transf Date |
|
|
|
Y |
|
BLOOD BANK; Date and time; date transfused; Point in time; QNT; Quan; Quant; Quantitative; Random; Time stamp; Timestamp; Transf Date; Tx |
2.26 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14688-6 |
Dehydroepiandrosterone sulfate |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14688-6 |
|
|
|
|
Both |
|
|
|
0 |
DHEA-S SerPl-sCnc |
|
|
|
Y |
|
adrenal dysfunction; Chemistry; DHEA; DHEAS; DHEA-S; DHEA-SO4; Endocrine; Endocrinology; Level; Pl; Plasma; Plsm; Point in time; Prasterone; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SO4; SO4-2; SR; Substance concentration; Sulf |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14689-4 |
Delta aminolevulinate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Delta aminolevulinate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
umol/24 H |
|
|
|
|
|
|
CHEM |
|
14689-4 |
|
|
|
|
Both |
|
|
|
0 |
D-ALA 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; 5-ALA; 5-aminolevulinate; 5-aminolevulinic acid; ALA; Aminolevulinic acid; Amnolev; Amnolevuunc; Chemistry; D-ALA; Delta-ala; Delta-aminolevulinic acid; Hematology; Heme; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/(24.h) |
|
|
|
0 |
1469-6 |
Follitropin^15M post 100 ug luteinizing releasing hormone IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Follitropin [Mass/volume] in Serum or Plasma --15 minutes post 100 ug luteinizing releasing hormone IV |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1469-6 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 15M p 100 ug LRH IV SerPl-mCnc |
|
|
|
Y |
|
15M p 100 ug LRH IV; After; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; Horm; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
14690-2 |
N-desalkylflurazepam |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
N-desalkylflurazepam [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14690-2 |
|
|
|
|
Both |
|
|
|
0 |
Desalkylfluraz SerPl-sCnc |
|
|
|
Y |
|
Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; Level; norfludiazepam; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14691-0 |
Desipramine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Desipramine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14691-0 |
|
|
|
|
Both |
|
|
|
0 |
Desipramine SerPl-sCnc |
|
|
|
Y |
|
Desi; Desip; Desipra; Desmethylimipramine; DRUG/TOXICOLOGY; Drugs; Imipramine metabolite; Level; Norpramin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14692-8 |
Desipramine |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Desipramine [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14692-8 |
|
|
|
|
Both |
|
|
|
0 |
Desipramine Ur-sCnc |
|
|
|
Y |
|
Desi; Desip; Desipra; Desmethylimipramine; DRUG/TOXICOLOGY; Drugs; Imipramine metabolite; Level; Norpramin; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.42 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14693-6 |
Norclobazam |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Norclobazam [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14693-6 |
|
|
|
|
Both |
|
|
|
0 |
Norclobazam SerPl-sCnc |
|
|
|
Y |
|
Clobazam metabolite; Desmeth; Desmethylclobazam; DRUG/TOXICOLOGY; Drugs; Level; N-desmethylclobazam; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14694-4 |
Norclomipramine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Norclomipramine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14694-4 |
|
|
|
|
Both |
|
|
|
0 |
Norclomipramine SerPl-sCnc |
|
|
|
Y |
|
Clomipramine metabolite; Desmeth; Desmethylclomip; Desmethylclomipramine; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14695-1 |
Nordoxepin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Nordoxepin [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14695-1 |
|
|
|
|
Both |
|
|
|
0 |
Nordoxepin SerPl-sCnc |
|
|
|
Y |
|
Desdoxepin; Desdoxepine; Desmeth; Desmethyl; Desmethyldox; Desmethyldoxepin; Doxepin metabolite; DRUG/TOXICOLOGY; Drugs; Level; N-desmethyldoxepin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14696-9 |
Deuteroporphyrin |
SCnc |
Stool |
Pt |
Qn |
|
|
ACTIVE |
Deuteroporphyrin [Moles/volume] in Stool |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14696-9 |
|
|
|
|
Observation |
|
|
|
0 |
Deuteropor Stl-sCnc |
|
|
|
Y |
|
Bowel movement; Chemistry; Faecal; Faeces; Fecal; Feces; Hematology; Heme; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal; Substance Concentration |
2.42 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14697-7 |
diazePAM |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
diazePAM [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14697-7 |
|
|
|
|
Both |
|
|
|
0 |
diazePAM SerPl-sCnc |
|
|
|
Y |
|
Addiction; c311; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stesolid; Substance concentration; Valium |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14698-5 |
Digoxin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Digoxin [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14698-5 |
|
|
|
|
Both |
|
|
|
0 |
Digoxin SerPl-sCnc |
|
|
|
Y |
|
Cardio; Cardiology; DGXN; DRUG/TOXICOLOGY; Drugs; Heart Disease; Lanoxin; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14699-3 |
diphenhydrAMINE+dimenhyDRINATE |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
diphenhydrAMINE+dimenhyDRINATE [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14699-3 |
|
|
|
|
Both |
|
|
|
0 |
Diphenhyd+Dimenhyd Gast Ql |
|
|
|
|
|
Benadryl; Diphenhyd+Dimenhyd; Diphenhydr; Diphenylhydramine; Dramamine; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.69 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Added TALLMAN lettering to dimenhyDRINATE; Previous Releases: The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
147-9 |
Cefuroxime.parenteral |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Cefuroxime Parenteral [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
147-9 |
|
SBT |
|
|
Observation |
|
|
|
0 |
Cefuroxime Parenter Titr SBT |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; c308; C33; Ceftin; Cefuroxime Axetil; Cefuroxime Parenter; Cefuroxime Sodium; Curoxim; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Islt; Isol; Kefurox; Point in time; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Titer; Titered; Titre; Ttr; Ultroxim; Zinacef |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
1470-4 |
Follitropin^1H post 100 ug luteinizing releasing hormone IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Follitropin [Mass/volume] in Serum or Plasma --1 hour post 100 ug luteinizing releasing hormone IV |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1470-4 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 1h p 100 ug LRH IV SerPl-mCnc |
|
|
|
Y |
|
1 hour; 1.0Hr; 1h p 100 ug LRH IV; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; Horm; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
14700-9 |
diphenhydrAMINE+dimenhyDRINATE |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
diphenhydrAMINE+dimenhyDRINATE [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14700-9 |
|
|
|
|
Both |
|
|
|
0 |
Diphenhyd+Dimenhyd SerPl Ql |
|
|
|
|
|
Benadryl; Diphenhyd+Dimenhyd; Diphenhydr; Diphenylhydramine; Dramamine; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.69 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Added TALLMAN lettering to dimenhyDRINATE; Previous Releases: The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14701-7 |
diphenhydrAMINE+dimenhyDRINATE |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
diphenhydrAMINE+dimenhyDRINATE [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14701-7 |
|
|
|
|
Both |
|
|
|
0 |
Diphenhyd+Dimenhyd Ur Ql |
|
|
|
|
|
Benadryl; Diphenhyd+Dimenhyd; Diphenhydr; Diphenylhydramine; Dramamine; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Added TALLMAN lettering to dimenhyDRINATE; Previous Releases: The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14702-5 |
Disopyramide |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Disopyramide [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14702-5 |
|
|
|
|
Both |
|
|
|
0 |
Disopyramide SerPl-sCnc |
|
|
|
Y |
|
Diso durules; DRUG/TOXICOLOGY; Drugs; Level; Norpace; Pl; Plasma; Plsm; Point in time; Pyramide; QNT; Quan; Quant; Quantitative; Random; Rythmodan; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14703-3 |
DOPamine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
DOPamine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14703-3 |
|
|
|
|
Both |
|
|
|
0 |
DOPamine SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14704-1 |
Doxepin |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Doxepin [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14704-1 |
|
|
|
|
Both |
|
|
|
0 |
Doxepin Gast Ql |
|
|
|
|
|
Adapin; Aponal; Dox; Doxpin; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Sinequan |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14705-8 |
Doxepin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Doxepin [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14705-8 |
|
|
|
|
Both |
|
|
|
0 |
Doxepin SerPl-sCnc |
|
|
|
Y |
|
Adapin; Aponal; Dox; Doxpin; DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sinequan; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |